StickIt Technologies Names New CEO and Announces Board Changes

VANCOUVER, BC September 17, 2026 - TheNewswire, StickIt Technologies Inc. announced a series of strategic changes aimed at accelerating commercial execution and strengthening corporate governance. These changes include the appointment of a new CEO and the addition of seasoned independent directors to the Board of Directors.

Effective July 10, 2026, Dr. Adi Zuloff-Shani has been appointed as Chief Executive Officer, succeeding Eli Ben-Haroosh, who resigned on April 1, 2026. Dr. Zuloff-Shani brings extensive executive leadership, biotechnology expertise, and operational acumen to drive StickIt's global joint venture strategy and commercial distribution. She has over two decades of experience leading therapeutic R&D across biotech and pharmaceutical companies, including her current role as CEO of Clearmind Medicine (NASDAQ: CMND).

In addition to the CEO appointment, the Board of Directors has been expanded with the addition of Mr. Gabriel Kabazo and Mr. Nir Eliyahu. Both are independent, non-executive directors, replacing all previous directors except Mr. Ohad David. Mr. Kabazo is an experienced finance and operations professional with over 25 years of experience, while Mr. Eliyahu has specialized in distribution channels and online sales for nine years (2012 to 2021) with Connect Inc. (USA) and Telem distribution in Vancouver.

The company has also completed key corporate recapitalization and financing milestones to optimize its balance sheet and fund ongoing operational and commercial activities. StickIt executed transactions under a letter of intent with Capitalink Ltd., acquiring rights to outstanding debt amounts previously owed by the company to corporate insiders, including executive directors, totaling approximately $617,000 for a restructured consideration of $380,000. This loan assignment substantially alleviates short-term liability pressures and simplifies the company's debt structure without triggering a fundamental change of corporate control.

Furthermore, StickIt closed a non-brokered private placement offering of securities, issuing 28,884,000 units at a price of CAD $0.025 per Unit, raising aggregate gross proceeds of CAD $722,100. Each unit consists of one common share and one full transferable common share purchase warrant, with each warrant entitling the holder to purchase one additional common share at an exercise price of CAD $0.025 for a period of 36 months from closing. To support capital restructuring, the company completed a share consolidation (1 post-consolidation share for 5 pre-consolidation shares) to increase equity structuring flexibility.

StickIt continues to enforce and broaden its competitive advantage through a robust global intellectual property strategy centered on its novel, patent-protected delivery vehicles for therapeutic compounds, plant extracts, and cannabinoid delivery systems. The company's core intellectual property includes a US granted patent (US11582996 B2) covering therapeutic plant extract delivery devices and specialized smoking utensil inserts.

StickIt's operating model involves establishing joint ventures in countries where recreational cannabis is permitted. Each licensee/joint venture partner will establish a production facility, adding cannabis content to sticks produced and supplied by StickIt. The company expects to provide the joint venture with the necessary know-how to manufacture the finished product. Licensees will produce the finished product, adding cannabis to the raw materials provided by StickIt, and will sell them either directly to points of sale or through distributors. Licensees are expected to pay a setup fee by investing the funds necessary to set up the local production facility. Each licensee will have exclusive rights to produce and market StickIt products in their designated territory.